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Description of the method to elaborate the evidence
The members of the Comissão de Esclerose Sistêmica da Socie-
dade Brasileira de Reumatologia (Systemic Sclerosis Commis-
sion of the Brazilian Society of Rheumatology, SBR) 2010-
2012 took part in the Evidence Preparation Course given 
by the Associação Médica Brasileira (Brazilian Medical Asso-
ciation, AMB) in São Paulo in the fi rst semester of 2011. The 
questions were formulated and discussed via internet in the 
second semester of 2011. The 15 clinical questions consid-
ered to be relevant were structured using the P.I.C.O. method 
(patient; intervention or indicator; comparison; outcome). 
The literature search was conducted by searching the data-
bases MEDLINE, EMBASE, SciElo/Lilacs, and the Cochrane Li-
brary through February, 2012 (Appendix). Critical assessment 
of the evidence in the selected articles was performed using 
the Jadad score. The observational studies and case series 
were considered for analysis when randomised clinical trials 
could not be located. A manual search located the relevant 
studies that were included in the analysis. The answers to 
the questions included in the Recommendations were re-
fi ned and elaborated, and all of the selected references ex-
hibited the corresponding grade of recommendation and the 
strength of scientifi c evidence. The references were updated 
through December, 2012, entered into a single fi le by the 
coordinator, and sent to the co-authors in four successive 
rounds for preparation of the fi nal version.
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Grades of recommendation and strength of evidence
A: Most consistent experimental and observational studies.
B: Less consistent experimental and observational studies.
C: Case reports (uncontrolled studies).
D: Opinion that is not substantiated by critical evaluation, 
based on consensus, physiological studies or animal 
models.
Objective
To establish recommendations for the management and 
treatment of systemic sclerosis.
Introduction
Systemic sclerosis (SSc), which is a chronic disease, affects 
the connective tissue and is characterised by manifestations 
derived from the fi brosis and dysfunction of the skin and in-
ternal organs. Its prevalence varies from 20 to 300 cases per 
one million adults. In 1980, the American College of Rheuma-
tology (ACR) formulated the classifi cation criteria for iden-
tifying patients with the well-established disease,1 which is 
classifi ed to be in limited or diffuse clinical form.2 In the 21st 
century, the scope of SSc was enhanced after the formulation 
of novel criteria for SSc sine scleroderma,3 early SSc,4 and very 
early SSc,5 which allow for the early diagnosis of a signifi cant 
number of patients.
SSc manifests a wide scope of skin (fi brosis and calcinosis), 
vascular (Raynaud’s phenomenon and ischaemic ulcers), and 
visceral characteristics (oesophageal and intestinal dysmotil-
ity, gastroesophageal refl ux, interstitial lung disease (ILD), 
pulmonary hypertension (PH), scleroderma renal crisis, myo-
cardial sclerosis, and heart arrhythmias).6 Nailfold capillaros-
copy7 and specifi c autoantibodies8 are also important tools for 
diagnosing and planning treatment. Of note, the treatment of 
SSc is based on organ-specifi c strategies because the various 
clinical manifestations might require different and specifi c 
medications. 
1. What are the classifi cation criteria for systemic 
sclerosis?
Several classifi cation criteria were formulated for the stratifi -
cation of SSc9 (A).
The classifi cation criteria most widely used in everyday 
clinical practice are the ones formulated in 1980 by the Amer-
ican Rheumatism Association (ARA), currently ACR (American 
College of Rheumatology)1 (D). Targeting the fi rst criteria with 
external validation, they established a pattern of disease defi -
nition that enables comparisons among groups of patients 
who are treated in different centres. Patients with SSc are 
thus classifi ed when they meet the one major criterion or two 
or more of the minor criteria:
• Major criterion: proximal scleroderma (skin symmetric fi -
brosis proximal to the metacarpophalangeal or metatarso-
phalangeal joints).
• Minor criteria:
 ± Sclerodactyly;
 ± Digital pitting or scars or loss of substance from digital 
fi nger pads (pulp loss); and 
 ± Bibasilar pulmonary fi brosis on chest x-rays. 
Following the criteria of LeRoy  et al.,3 SSc is classifi ed into 
two subsets. Diffuse cutaneous SSc (dcSSc) is defi ned by the 
onset of Raynaud’s phenomenon within 1 year of the appear-
ance of skin changes that quickly progress with truncal and 
acral skin involvement, presence of tendon friction rubs, and 
early visceral infection (lung fi brosis, SRC, diffuse gastrointes-
tinal disease, and myocardial sclerosis). In turn, the patients 
with limited cutaneous SSc (lcSSc) might exhibit Raynaud’s 
phenomenon for years, slow-progressing skin infection re-
stricted to the limbs (below the elbow and knees) and the 
face, or absent, signifi cant late incidence of pulmonary artery 
hypertension (PAH), calcinosis, telangiectasia, and a high in-
cidence of anti-centromere antibodies (ACA)2 (B). The preva-
lence of dcSSc, lcSSc, and SSc, combined with another con-
nective tissue disorder, was observed to be 36.9%, 57.5%, and 
5.6%, respectively10 (B).
A recent assessment of SSc-specifi c antibodies showed 
differential distribution parallel to the LeRoy’s subsets of dis-
ease: ACA were detected in 46.7% of the patients classifi ed 
as lcSSc versus 6% in the those classifi ed as dcSSc, and the 
anti-topoisomerase I antibodies (anti-Scl-70) were detected in 
23.4% of the patients classifi ed as lcSSc versus 60.8% of the 
those classifi ed as dcSSc6 (B). 
The criteria for the diagnosis of SSc sine scleroderma 
(ssSSc) were formulated in 2000. In this infrequent variety, 
the specifi c visceral infection is not attended by skin involve-
ment. Clinically, ssSSc is characterised by the presence of ob-
jective Raynaud’s phenomenon, positive anti-nuclear factor, 
and at least one organ exhibiting SSc specifi c infections, such 
as distal oesophageal hypomotility, small-bowel hypomotility, 
ILD, primary PH, myocardial sclerosis, or SRC3 (B).
In 2001, LeRoy and Medsger formulated the criteria for 
early SSc that allow for the classifi cation of patients in the 
early stages of SSc before the appearance of the typical skin or 
visceral manifestations and based on the following:
• Objective evidence of Raynaud’s phenomenon (observed 
by the doctor) and scleroderma pattern of microangiopa-
thy on nailfold capillaroscopy (NFC) or SSc-specifi c auto-
antibodies (ACA, anti-Scl-70, anti-RNA polymerase III) or 
• Subjective evidence of Raynaud’s phenomenon (reported 
in the clinical interview but not observed by the doctor) 
and scleroderma pattern of microangiopathy on NFC and 
SSc-specifi c autoantibodies4 (B).
In several cases, the criteria for early SSc and ssSSc over-
lap. Whether ssSSc should to be included within the scope of 
lcSSc with a limited cutaneous involvement or whether ssSSc 
should be considered to be a distinct condition is a subject of 
current debate. 
Finally, the European League Against Rheumatism (EULAR) 
and the EULAR Scleroderma Trial and Research (EUSTAR) 
group formulated non-validated classifi cation criteria for very 
early SSc that include laboratory tests and NFC. The presence 
of Raynaud’s phenomenon, fi nger swelling, and positive ANF 
indicate the need to investigate the specifi c antibodies (ACA 
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and anti-Scl-70) and to perform NFC. The presence of positive 
specifi c antibodies or the presence of scleroderma pattern on 
NFC leads to the classifi cation of very early SSc and indicates 
the need to investigate visceral involvement5 (B).
Recommendation 1
Classifi cation of SSc in limited and diffuse subsets best re-
fl ects the natural history of the disease and exhibits clear 
clinical differences. Positive-specifi c antibodies (anti-centro-
mere and anti-Scl-70) and the scleroderma pattern of micro-
angiopathy on NFC are reliable confi rmatory criteria of SSc in 
the very early stage of the disease. 
2. What is the role of nailfold capillaroscopy in 
the early diagnosis and follow-up of systemic 
sclerosis?
NFC allows for the early differential diagnosis between indi-
viduals with primary and secondary Raynaud’s phenomenon. 
The scleroderma pattern of microangiopathy on NFC exhib-
its a high correlation with progression into SSc (P = 0.00001, 
94% sensitivity, 92% specifi city, 52% positive-predictive value, 
99% negative-predictive value [odds ratio (OR), 163; 95% con-
fi dence interval (CI), 97.89-271.47])11,12 (A). The presence of an-
tinuclear antibodies (ANA) has a prognostic impact (hazard 
ratio (HR), 9.70) when it is associated with the scleroderma 
pattern of microangiopathy in patients with primary Rayn-
aud’s progressing into SSc13 (A).
The early appearance of dilated megacapillaries and mi-
crohemorrhages on NFC is of paramount importance in the 
early diagnosis of SSc. These fi ndings are more frequent in 
the active stage of the disease, whereas the presence of areas 
with capillary devascularisation, destructuration of the capil-
lary bed architecture, and the presence of branching capillary 
loops and bushy loops correspond to the vascular damage as-
sociated with the advanced stages of SSc14 (A).
NFC might be performed using different types of equip-
ment, including stereomicroscopes, video-capillaroscopes, 
and dermatoscopes7 (A). The former two are considered to 
exhibit better sensitivity and accuracy in the assessment of 
the peripheral microangiopathy associated with the sclero-
derma pattern13 (A). One study found satisfactory accuracy 
in the assessment of the nailfold capillaries using derma-
toscopy, with 83.1% sensitivity and 100% specifi city in the 
diagnosis of SSc15 (A). 
According to several studies, there is a correlation between 
changes in NFC and risk of fi nger ulcers. The reproducibility of 
the capillaroscopic skin ulcer risk index (CSURI) has been vali-
dated. This index is calculated using the equation: D × M/N2, 
where D is the maximum loop diameter of megacapillaries, M 
is the number of megacapillaries (diameter ≥ 50 μm), and N 
is the total number of capillaries in the distal row. This index 
was found to be highly predictive of the appearance of digital 
ulcers in SSc 3 months after assessment using a videocapil-
laroscopy (92.9% sensitivity [95% CI, 83.0-98.0]; 81.4% speci-
fi city [95% CI, 74.8-86.8]; cut-off point: 2.96, and area under 
receiver operator characteristic (ROC) curve: 0.884 [95% CI, 
0.835-0.922])16,17 (A). 
NFC is also considered to be useful for assessing the severity 
of SSc. In patients with SSc for ≤ 5 years, a study found a posi-
tive correlation between the capillaroscopic changes observed 
using a stereomicroscopy and the presence of ground-glass in-
fi ltrates on high-resolution chest tomography, thus suggesting 
that NFC might be useful in the identifi cation of predictors of 
lung involvement18 (A). A similar correlation was found relative 
to the degree of involvement of other target organs (digestive 
system, kidney, and musculoskeletal system) [P < 0.01]19 (A).
Recommendation 2
NFC allows for the early diagnosis of SSc and is useful for as-
sessing its severity and prognosis.
3. What is the role of autoantibodies in the early 
diagnosis and follow-up of patients with systemic 
sclerosis?
The detection and quantifi cation of specifi c antibodies be-
came signifi cant tools for the diagnosis, classifi cation, and 
prognosis of SSc10 (B).
SSc-specifi c antibodies
Anti-centromere antibodies
Anti-centromere antibodies (ACA) are detected in 60-82% 
of the patients with lcSSc and in 2-7% of the patients with 
dcSSc6 (B). A specifi c pattern on indirect immunofl uores-
cence (IFI) using HEp-2 cells allows for the identifi cation of 
ACA20,21 (B).
ACA-positive patients exhibit longer latency period (aver-
age, 6.5 ± 10 years) before the fi rst manifestation, in addition 
to Raynaud’s phenomenon, compared to the patients with 
anti-Scl-70 antibodies (average, 2.4 ± 5.6 years). For this rea-
son, the diagnosis might be delayed in many cases6,22 (B).
Several studies reported an association between positive 
ACA and the presence of calcinosis, PAH, and fi nger ulcers6,22 
(B). 
Anti-DNA topoisomerase I antibodies
The sensitivity of anti-DNA topoisomerase I antibodies (anti-
Scl-70), which are assessed using double immunodiffusion or 
immunoblot, is variable because they are detected in 26-76% of 
the patients, with a specifi city of 98-99.6%6,23,24 (B). They might 
be detected in 40-70% of the patients with dcSSc and 36% of the 
patients with lcSSc6,23 (B). The presence of anti-Scl-70 is associ-
ated with a higher prevalence of faster skin and visceral infec-
tion, myositis, lung fi brosis, and pericarditis24 (B).
Other autoantibodies associated with SSc
Anti-RNA polymerase
There are three types of RNA polymerase (I, II, and III). The 
presence of anti-RNA polymerase I/II/III antibodies is associ-
ated with dcSSc (77.8%; other groups, 12.4%; P < 0.001; relative 
risk (RR), 6.3). Anti-RNA polymerase I and II-positive patients 
also exhibit a higher incidence of dcSSc, however, without 
statistical signifi cance (dcSSc, 42.9%; other groups, 15.7%)25 (B). 
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Anti-RNA polymerase-positive patients exhibit a signifi cantly 
higher incidence of kidney involvement (29.0%; other, 11.3%; 
P < 0.05; RR, 2.6), and the probability of kidney disease of anti-
RNA polymerase I/II/III-positive patients is 40%25 (B). 
Anti-U3RNP (fi brillarin) antibodies
These antibodies are more frequently detected in younger, 
male, and black patients. The presence of anti-fi brillarin anti-
bodies bears a correlation with dcSSc and occurs in < 10% of 
the patients with SSc26,27 (B).
Anti-Th/To antibodies
These antibodies bear a correlation with poor prognostic lc-
SSc and more severe ILD and PH8,28 (D).
Recommendation 3
The investigation of specifi c autoantibodies helps in the di-
agnosis of SSc. Anti-centromere antibodies are classically 
associated with the limited form of the disease, whereas 
anti-Scl-70 is strongly associated with diffuse SSc and has 
signifi cant prognostic value (faster skin and visceral involve-
ment, myositis, lung fi brosis, and pericarditis). Anti-RNA poly-
merase autoantibodies are associated with the diffuse form of 
the disease and kidney involvement. 
4. What treatments are benefi cial for skin 
thickening in systemic sclerosis?  
The modifi ed Rodnan total skin score (MRTSS) assesses skin 
thickness by palpation of 17 body sites (fi ngers, back of the 
hands, arms, forearms, feet, legs, thighs, face, chest, and abdo-
men) on a scale varying from 0 to 3, where 0 = normal, 1 = mild 
thickness, 2 = moderate thickness, and 3 = severe thickness. The 
MRTSS varies from 0 (no thickness) to 51 (severe thickness in 
all 17 sites)29 (B). Skin thickness might also be assessed using a 
hand-held digital durometer that measures the hardness of the 
skin at six body sites (forearms, thighs, and legs) on a continu-
ous scale. The total score is derived from the sum of the average 
measure of the six investigated sites30 (B). 
Two clinical studies investigated the effect of methotrexate 
on the skin component of SSc. One study assessed the effect of 
methotrexate per intramuscular (IM) route in the dose of 15 mg 
per week, eventually increased to 25 mg per week in 29 patients 
with SSc for > 3 years, and skin thickening or persistent fi nger 
ulcers in the last 6 months. After 24 weeks of treatment, 68% of 
the volunteers exhibited ≥ 30% improvement in the total skin 
score, which corresponded to the sum of the skin thickness 
scores in 26 body sites on a scale of 0 to 4 scale (original Rodnan 
score)31 (B). The other study assessed treatment with metho-
trexate, 10 mg per week, over 2 months (increasing to 15 mg per 
week) in 71 patients with SSc and a minimum of 5 points on the 
UCLA score. The results showed that treatment with metho-
trexate induced a signifi cant reduction of 22.5% in the MRTSS 
and 20% in the UCLA score compared to the untreated group 
after a 12-month follow-up32 (A).
Patients with SSc and treated with D-penicillamine (250 
mg/day or 125 mg on alternate days) on a daily basis (increas-
ing from one capsule in the two fi rst months to two capsules 
on months 3 and 4, three capsules on months 5 to 7 and four 
capsules on the ensuing months, totalling 1,000 mg in the fi rst 
group) over 24 months exhibited the same results on MRTSS 
with either dose (score reduction of 4.8 ± 10.3 with the high 
dose, and 6.9 ± 8.4 with the low dose)33 (A). As a function of that 
similarity of the results of the high and low (considered to act 
as a placebo) doses and the high index of side effects associated 
with the use of D-penicillamine, most rheumatologists stopped 
prescribing this drug in the last decade. 
Recombinant human relaxin in doses of 25 mg/kg/day or 
100 mg/kg/day as continuous subcutaneous (SC) infusion was 
tested in patients with SSc for > 5 years and MRTSS of at least 20 
compared to no treatment over 24 weeks. The lower tested dose 
of 25 mg/kg/day reduced the skin score compared to the un-
treated volunteers (reduction of 23.6%, 27.5%, and 28.7% during 
weeks 4, 12, and 24, respectively), whereas the volunteers who 
received 100 mg/kg/day did not exhibit any benefi t when com-
pared to the untreated patients34 (A) and MRTSS was similar in 
the treated and untreated groups during weeks 4, 12, and 24. 
The discontinuation of relaxin during week 24 induced severe 
side effects with kidney infection manifested as reduced cre-
atinine clearance and renal crisis, or grade 3 or 4 arterial hyper-
tension35 (A). Because the recombinant human relaxin was not 
shown to be better than placebo relative to the skin and visceral 
manifestations of dcSSc and its discontinuation was associated 
with severe renal side effects, relaxin was not indicated for the 
treatment of SSc. 
In patients with SSc and MRTSS of ≥ 16, treatment using oral 
type I collagen in a dose of 500 μg/day over 12 months was not 
associated with changes in the score. Nevertheless, an analy-
sis of the subgroup of patients who exhibited SSc for 3 to 10 
years showed a signifi cant score reduction (7.9 vs. 2.9)36 (A). The 
use of collagen as antifi brotic medication provides a satisfac-
tory therapeutic perspective that must still be more properly 
investigated. 
The use of intravenous (IV) infusions of iloprost in doses 
of 0.5 ng/kg/min or 2 ng/kg/min once per day over 21 days did 
not induce MRTSS changes in patients with SSc after 1 year of 
follow-up37 (B).
A double-blind, randomised, placebo-controlled trial using 
oral cyclophosphamide on a daily basis in 158 patients and 
whose primary outcome was the drug effect on ILD observed 
a signifi cant improvement (P < 0.01) of the skin score after 12 
months and 24 months of follow-up. Improvement disappeared 
after drug discontinuation38 (A) and was more signifi cant in the 
patients with dcSSc39 (A). 
An open-label study that assessed 25 treatment-naïve pa-
tients with recent SSc (< 24 months) using mycophenolate 
mofetil (average dose, 2.0 g/day; average length of use, 18.2 ± 8.7 
months) reported signifi cant improvement in the MRTSS (from 
24.5 ± 8.6 at baseline to 14.5 ± 10.9 at the end of treatment) and 
affected skin area (from 36 ± 16% to 14 ± 13.3%) in 15 patients 
who completed the study. The results of the lung function test 
remained stable throughout the study, and the skin biopsy of 
three patients exhibited a remarkable reduction of the collagen 
fi bre accumulation40 (B). 
Following 1 year of treatment with rituximab (375 mg/m2), 
the MRTSS of patients with SSc and ILD exhibited reductions of 
5.13 and 8.65 at 1 and 2 years of follow-up, respectively. The per-
centage of improvement using rituximab was 18.45%41,42 (A).
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An open-label phase IIa study assessing imatinib mesyl-
ate in a dose of 400 mg/day in 30 patients with dcSSc over 
12 months demonstrated a reduction of MRTSS (6.6 points or 
22.4%) at the end of treatment for 24 patients who completed 
the study. The improvement was more evident after 6 months 
of treatment, in both the patients with recent and late-phase 
disease43 (B). A total of 171 adverse events were observed, of 
which 24 were severe.
Another open-label phase I/IIa study that assessed 20 pa-
tients with SSc and active ILD using imatinib mesylate showed 
an average reduction of 3.9 points in the MRTSS (baseline 18.7 
± 10.1) of the 12 patients who completed the study (P < 0.001)44 
(B). Seven patients did not complete the study due to side 
effects. Common side effects, such as fatigue, face swelling, 
nausea and vomiting, diarrhoea, generalised rash, and pro-
teinuria, occurred in > 20% of the volunteers and are associ-
ated with doses of > 600 mg/day. 
Recommendation 4
Methotrexate is the fi rst drug of choice for progressive skin 
thickening in patients with SSc. Cyclophosphamide, myco-
phenolate mofetil, and rituximab might represent options for 
the patients who do not respond to methotrexate. 
5. What treatments are benefi cial for 
subcutaneous calcinosis in systemic sclerosis?
Pharmacological treatment
The data on the effect of warfarin for the treatment of cal-
cinosis in patients with SSc are confl icting. Although three 
studies reported improvement of calcinosis with the use of 
low doses (1 mg/day; 12-18 months)45-47 (C), a fourth study did 
not fi nd that treatment effective48 (C). Treatment with warfa-
rin is more effective in patients at the early stages of calcino-
sis. No study using low doses reported increased bleeding or 
changes in the coagulation time.
The patients with lcSSc who used diltiazem in a dose of 
240-480 mg/day for 1 or 2 years had reduced or improved cal-
cinosis with consequent clinical benefi ts49 (C). A lower dose 
(180 mg/day) was not able to induce a similar clinical response 
but only slight radiological improvement50 (C).
In patients with SSc and calcinosis, cycles of minocycline 
(50 or 100 mg/day) (treatment over 4 to 8 weeks, followed by 
interruption over 3 to 4 months) reduced ulcers and infl am-
mation but induced a slight reduction of calcinosis51 (C).
Colchicine per oral route in a dose of 1 mg/day over 3 
months improved the healing of ulcers and reduced the asso-
ciated infl ammation in patients with SSc and calcinosis52 (C).
Other agents, such as bisphosphonates (risedronate), IV 
immunoglobulin, and rituximab, were associated with re-
duced calcinosis in several patients with lcSSc, as demon-
strated in the results of case reports53 (C).
Non-pharmacological treatment 
Surgery should be taken into consideration as an option after 
several instances of therapeutic failure, provided calcifi ca-
tions are well delimited because surgery increases the risk of 
infection and skin necrosis54 (C).
Carbon dioxide laser (CO2 laser) might be used to “vapo-
rise” superfi cial calcinosis in patients with CREST syndrome 
(calcinosis, Raynaud’s, oesophageal dysmotility, sclerodactyly, 
and telangiectasia)55 (C).
Extracorporeal shock wave lithotripsy (ESWL), which might 
be effective, is associated with low morbidity in patients with 
CREST syndrome and ulcerated calcinosis, thus reducing the 
number of calcifi cations and the size of ulcerations56 (C).
Recommendation 5
Warfarin might be effective in the early stage of calcinosis, 
and diltiazem might reduce or improve calcinosis, whereas 
minocycline and colchicine improve the healing of ulcer-
ations and the infl ammation that is associated with calcino-
sis. No treatment proved to be entirely effective against cal-
cinosis in SSc. 
6. What treatments are benefi cial for Raynaud’s 
phenomenon in systemic sclerosis?
Calcium-channel blockers 
Calcium-channel blockers, dihydropyridines in particular, 
are effi cacious in the treatment of Raynaud’s phenomenon 
secondary to SSc.57 The calcium-channel blockers reportedly 
reduced the number (weighted mean difference [WMD], −8.31; 
95% CI, −15.71 to −0.91; P = 0.03) and the severity of ischaemic 
episodes by 35% (standard mean difference [SMD], −0.69; 95% CI, 
−1.21 to −0.17; P = 0.01) in up to 2 weeks of treatment. Nife-
dipine in a dose of 10-20 mg three times per day has shown to 
reduce the number of ischaemic episodes (WMD, −10.21; 95% 
CI, −20.09 to −0.34; P = 0.04) after 2 to 12 weeks of treatment57 
(B). Nifedipine is the fi rst drug of choice to treat Raynaud’s 
phenomenon in patients with SSc. 
In a randomised clinical trial, nicardipine did not induce 
a statistically signifi cant (P > 0.05) reduction of the frequency 
and severity of ischaemic episodes58 (B).
Compared to placebo, diltiazem did not show effi cacy in 
the reduction of the frequency or severity of Raynaud’s phe-
nomenon in a clinical study59 (B). Despite the lack of controlled 
clinical studies, amlodipine might represent an alternative to 
nifedipine in the treatment of Raynaud’s phenomenon60 (D).
Prostacyclin analogues
One randomised, placebo-controlled trial showed that IV ilo-
prost in a dose of 0.5-2 ng/kg/min over 6 hours for 5 consecu-
tive days reduced the average number (39.1-22.2%; P = 0.005) 
and severity (34.8-19%; P = 0.01) of ischaemic episodes in 9 
weeks61 (B). After 3 months, treatment with a low dose (0.5 ng/
kg/min) of IV iloprost infused over 6 hours proved to be as ef-
fi cacious as the higher doses (maximum-tolerated dose of 2 
ng/kg/min). Both regimens reduced the frequency (40%) and 
length (30%) of Raynaud’s phenomenon up to 1 week after 
the end of treatment37 (B). However, iloprost is not marketed 
in Brazil, and the consequent unfavourable cost/benefi t ratio 
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limits its indication for patients with severe Raynaud’s phe-
nomenon associated with SSc. 
Oral iloprost in a 50-μg dose twice per day over 6 weeks 
did not reduce the length, frequency, or severity of ischaemic 
episodes at 6 and 12 months (P > 0.05 in all the outcomes)62 (B).
Intravenous iloprost (2 ng/kg/min over 8 hours for 3 to 5 
consecutive days, and subsequently once per day every 6 to 
8 weeks) proved to be slightly better (P = 0.04) compared to 
nifedipine (30-60 mg/day) to control Raynaud’s phenomenon 
in patients with SSc63,64 (B).
The side effects related with iloprost were nausea and 
vomiting (83%), jaw pain (69%), muscle pain (34%), diarrhoea 
(28%), and chills (17%). Tachycardia was reported in 6% of the 
patients using nifedipine63,64 (B).
Alpha-adrenergic blockers
Two studies that used prazosin for the treatment of Raynaud’s 
phenomenon showed modest results65 (A). In another study 
with a larger number of patients (n = 20), prazosin adminis-
tered orally (3 mg/day over 8 weeks) induced a reduction of 
the weekly Raynaud’s phenomenon attack frequency (mean 
difference [MD], −3.5; 95% CI, −5.85 to −1.15), and a side effect 
rate of 18%66 (B).
Endothelin receptor antagonists 
Bosentan, an oral endothelin receptor antagonist (ERA), in a 
dose of 62.5 mg twice per day over 4 weeks followed by 125 mg 
twice per day over 12 weeks, did not improve the frequency, 
length, associated pain, or severity of Raynaud’s phenomenon 
attacks in patients with SSc and Raynaud’s without pre-exist-
ing fi nger ulcers (P > 0.05)67 (B).
Angiotensin I-converting enzyme (ACE) inhibitors and 
angiotensin II-receptor antagonists
Quinapril in a dose of 80 mg/day or in the maximum-tolerat-
ed dose did not reduce the frequency (MD, 0.3; 95% CI, –5.6 to 
6.3) and the severity (MD, 0.1; 95% CI, -6.1 to 6.3) of Raynaud’s 
attacks68 (B).
Losartan (50 mg/day) did not induce a signifi cant differ-
ence in the frequency and the severity of the attacks of Rayn-
aud’s phenomenon secondary to SSc at 3 and 15 weeks com-
pared to nifedipine (40 mg/day) (P > 0.05)69 (B).
Phosphodiesterase inhibitors
One clinical study using tadalafi l in a dose of 20 mg on al-
ternate days over 6 weeks in a small number of patients 
with SSc or mixed connective tissue disease (MCTD) using 
calcium-channel blockers (72% also using other vasodila-
tors) reported a reduction of the frequency (2.29 vs. 3.37; P 
= 0.0004), duration (34 min vs. 55 min; P = 0.02), and sever-
ity (P < 0.0005) of the Raynaud’s phenomenon episodes70 (B). 
Another clinical study using tadalafi l as monotherapy in a 
dose of 20 mg/day over 4 weeks in women with Raynaud’s 
secondary to SSc did not fi nd a reduction of the frequency (P 
= NS), duration (P = NS), or severity (P = NS) of the ischaemic 
episodes71 (B).
An analysis of clinical trials with small numbers of volun-
teers, open-label studies, and case reports assessing sildenafi l 
demonstrated reductions of the severity and number of Rayn-
aud’s attacks in patients with SSc72 (D).
The use of extended-release sildenafi l in a dose of 100 
mg/day over 3 days followed by 200 mg/day over 25 days in 
patients with Raynaud’s phenomenon secondary to lcSSc re-
duced the weekly frequency of the episodes (44% vs. 18.1%; P 
= 0.034) but did not reduce their duration nor the associated 
pain (P = NS)73 (B). Although the extended-release sildenafi l is 
a good option for patients with SSc who are unresponsive to 
calcium-channel blockers, sildenafi l is not marketed in Brazil. 
Other drugs 
Cyclofenyl is not effective in the treatment of Raynaud’s phe-
nomenon secondary to SSc74 (B). 
Ketanserin did not reduce the frequency [(fi xed) MD, 25.20 
(95% IC 22.55, 27.85)] and the duration [(fi xed) MD, 4.10 (95% 
CI, 3.57, 4.63)] of Raynaud’s phenomenon secondary to SSc75 
(A).
Compared to placebo, atorvastatin did not improve the se-
verity of Raynaud’s phenomenon secondary to SSc (MD, −0.8; 
95% CI, −2.52 to 0.92; P = 0.35)76 (B).
The use of antioxidants (selenium, beta-carotene, vitamin 
E, vitamin C, and methionine associated with allopurinol) did 
not reduce the number and the duration of Raynaud’s attacks 
in up to 10 weeks in patients with SSc77 (B). 
Recommendation 6
Calcium-channel blockers might reduce the frequency and 
the severity of ischaemic episodes in patients with Raynaud’s 
phenomenon secondary to SSc. They should be the fi rst drugs 
of choice for the treatment of Raynaud’s phenomenon in SSc.
Intravenous iloprost reduced the number and the sever-
ity of the ischaemic episodes. The low doses are as effi cient 
as the higher doses in patients with Raynaud’s phenomenon 
secondary to SSc. Iloprost is not marketed in Brazil. 
The use of extended-release sildenafi l reduces the fre-
quency of attacks in patients with Raynaud’s phenomenon 
secondary to SSc. Sildenafi l is not available in Brazil. 
7. What treatments are benefi cial for ischaemic 
ulcers in systemic sclerosis?
Prostacyclin analogues
Two randomised clinical trials demonstrated benefi cial ef-
fects of IV iloprost in the treatment of ischaemic ulcers. In one 
study, iloprost in IV infusion (0.5-2 ng/kg/min) over 6 hours for 
5 consecutive days) was associated with 85% increase in the 
number of patients with full healing of the fi nger skin isch-
aemic injury (ulcer, fi ssure, or paronychia) compared to place-
bo (number needed to treat, NNT= 1) in up to 10 weeks78 (B). In 
the other study, the group that used iloprost exhibited 14.7% 
more patients with healing of at least 50% of the fi nger lesions 
in up to 3 months compared to the group that used placebo; 
this difference was not statistically signifi cant (P = 0.06)61 (B). 
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Iloprost per IV route did not reduce the number of patients 
who developed new lesions in up to 9 months (NNT = NS)61 (B).
Treatment using IV iloprost over 6 hours in low dose (0.5 
ng/kg/min) over 3 weeks was as effi cient as the higher doses 
(maximum-tolerated dose of 2 ng/kg/min). Iloprost in high 
dose reduced by 76.2% and the low dose reduced by 61% the 
number of fi nger ulcers 1 week after the end of treatment. 
The reduction in the number of fi nger ulcers did not exhibit 
a signifi cant difference between the high and low doses (P = 
NS)37 (B).
A comparison of IV iloprost (0.5-2 ng/kg/min over 8 hours 
on 3 consecutive days, and one additional infusion in week 
8) and nifedipine (30 mg/day increasing to 60 mg/day after 
4 weeks over 12 weeks) demonstrated a reduction of the 
number of fi nger lesions (ulcers, fi ssures, and paronychia) 
in both groups, without a signifi cant difference between the 
treatments in 16 weeks (MD, −0.8; 95% CI, −2.09 to 0.49, P = 
0.20)64 (B).
The use of alprostadil (prostaglandin E1) in IV infusion was 
associated with improvement of symptoms in 17 of 20 infu-
sions performed in a total of 12 patients, and healing of 35 of 
65 ischaemic ulcers between 2 and 6 weeks after the end of 
treatment, and the benefi ts persisted from 1 to 18 months79 
(C). A clinical study that compared the effi cacy of iloprost and 
IV alprostadil in patients with Raynaud’s phenomenon and 
fi nger ulcers reported signifi cant improvement of ulcer heal-
ing in both groups80 (B). Because iloprost is not marketed in 
Brazil, the IV infusion of alprostadil represents a therapeutic 
option for severe ischaemic ulcers refractory to conventional 
treatment. 
Endothelin receptor antagonists
Bosentan was assessed in two randomised clinical trials in-
cluding patients with SSC. In patients with SSc and at least 
one active fi nger ulcer, bosentan (62.5 mg PO twice per day 
during 4 weeks, and 125 mg twice per day for > 20 weeks) 
reduced the number of new fi nger ulcers by 30% compared to 
the placebo (mean ± standard error [SE], 1.9 ± 0.2 vs. 2.7 ± 0.3; 
P = 0.04) in up to 24 weeks. The investigated treatment did not 
infl uence the time needed for complete healing of all the ex-
istent (HR, 0.94; 95% CI, 0.65-1.37; P = 0.74) or new fi nger ulcers 
(HR, 1.40; 95% CI, 0.78-2.51; P = 0.26) in up to 24 weeks81,82 (A). 
Phosphodiesterase inhibitors
In a cross-over study with a small number of patients with 
SSc or MCTD using calcium- channel blockers (72% also using 
other vasodilators), tadalafi l (20 mg on alternate days over 6 
weeks) associated with healing of 100% of the fi nger lesions 
(ulcers or fi ssures) compared to 23% in the group that used 
placebo (P < 0.001, NNT = 2), and prevented the development 
of new ischaemic lesions in 92% of the patients (P = 0.001)70 
(B). Because the action of tadalafi l as a single vasodilator in 
the treatment of ischaemic ulcers in SSc has not yet been as-
sessed, its effi cacy has not yet been established. 
In an open-label study including 19 patients with SSc and 
fi nger ulcers refractory to conventional treatment, treatment 
with sildenafi l (50-100 mg/day) was associated with a signifi -
cant reduction of the number of ulcers after 6 months83 (B).
Other medications 
Atorvastatin (40 mg/day over 4 months) reduced the total 
number of fi nger ulcers (MD, −0.6; 95% CI, −1.15 to −0.04; P = 
0.03), as well as the number of new ones (P = 0.003) compared 
to placebo after 4 months in a single clinical study76 (B). 
Recommendation 7
In patients with SSc, intravenous iloprost increases the num-
ber of healed active fi nger ulcers. The low doses are as effi ca-
cious as the higher doses. There is no difference in the re-
duction of the number of fi nger lesions between intravenous 
iloprost and nifedipine. Iloprost is not available in Brazil. 
Due to the unavailability of iloprost in Brazil, intravenous 
alprostadil might represent an option for the treatment of se-
vere ischaemic ulcers refractory to conventional treatment.
In patients with SSc, bosentan decreases the development 
of new fi nger ulcers.
The use of sildenafi l might contribute toward reducing the 
number of fi nger ulcers. 
8. What are the maintenance treatments to 
prevent the recurrence of ischaemic ulcers in 
systemic sclerosis?
Endothelin receptor antagonists
Two randomised clinical trials that compared bosentan versus 
placebo demonstrated a signifi cant reduction of the number 
of new fi nger ulcers in the group of patients with SSc treated 
with bosentan. One study included 122 patients with dcSSc or 
lcSSc and a previous history of fi nger ulcers; treatment with 
bosentan over 12 weeks reduced the number of new lesions 
by 48%, especially in the volunteers with diffuse disease and 
multiple fi nger ulcers [RAPIDS-1 study]81 (A).
In the other study, patients with at least one active isch-
aemic fi nger ulcer treated with bosentan over 24 weeks ex-
hibited a 30% reduction of the number of new lesions. The 
results were better in the patients with multiple fi nger ulcers 
[RAPIDS-2 study]82 (A).
The recommended dose of bosentan is 62.5 mg twice per 
day for 1 month, and 125 mg twice per day from the second 
month onward. Adverse effects included increased trans-
aminase levels (14-12.5%), diarrhoea (9%), peripheral swelling 
(18.8%), ventricular tachycardia, and pneumonia81,82 (A).
Recommendation 8
Endothelin receptor antagonists, bosentan in particular, are 
recommended as treatment to prevent the recurrence of isch-
aemic ulcers. 
9. What treatments are benefi cial for oesophageal 
and intestinal hypomotility in systemic sclerosis? 
Metoclopramide improves the oesophageal lower sphincter 
pressure and the stomach emptying but it does not improve 
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the oesophageal motility84,85 (C). Despite the lack of high-qual-
ity randomised clinical studies, metoclopramide and dom-
peridone 30 min before meals is the standard maintenance 
treatment for patients with oesophageal hypomotility. 
Long-term (6 months) use of long-acting octreotide, which 
is a somatostatin analogue, might improve the symptoms and 
quality of life for patients with SSc and small-bowel disease 
that are non-responsive to prokinetic agents86 (C). A combi-
nation of octreotide with erythromycin might improve the 
symptoms associated with intestinal pseudo-obstruction 
(distension, abdominal pain, and nausea)87 (C).
Recommendation 9
Prokinetic agents (metoclopramide, domperidone, and oc-
treotide) should be used to relieve the symptoms associated 
with gastrointestinal dysmotility. 
10. What treatments are benefi cial for 
gastroesophageal refl ux and its complications in 
systemic sclerosis?
Patients with SSc for an average of 6 years, who did not use 
medication and who exhibited oesophageal involvement of 
different stages of severity (stages I to IV), presented variable 
types of respiratory infections. Lung infection was 30-40% 
greater in the severe stages of oesophageal disease, includ-
ing gastroesophageal refl ux (GER) with progressive deterio-
ration, and decline of the respiratory function after a 2-year 
follow-up88 (B).
The treatment of SSc and history of GER accompanied 
by typical symptoms, such as heartburn or acid regurgita-
tion with omeprazole 20 mg twice per day over 6 weeks, or 
omeprazole 20 mg combined with ranitidine 300 mg, resulted 
in increased quality of life scores and symptom relief with no 
difference between both regimens89,90(B).
The gastrointestinal system is one of the sites most often 
affected in SSc. Approximately 44% of the patients exhibit GER 
and 15% present with oesophageal dysmotility. Proton pump 
inhibitors (PPIs) might be used to improve the symptoms of 
GER and oesophagitis. Treatment with lansoprazole, 30 mg/
day, is associated with improvement of symptoms (heartburn, 
regurgitation, and dysphagia) and increase in the frequency 
of diarrhoea after 6 months, and worsening of dysphagia after 
12 months91(B).
Barrett’s oesophagus is a complication of chronic GER 
that also appears in patients with SSc. During the 3-year fol-
low-up of a population of such patients, high-grade dyspla-
sia or oesophageal adenocarcinoma was diagnosed in 3% of 
the sample per year, and the incidence of adenocarcinoma 
exhibited a progressive increase in the patients with dyspla-
sia92 (B).
Patients with SSc and oesophageal complaints, mainly 
GER non-responsive to pharmacological treatment, might be 
subjected to several surgical procedures, including oesopha-
gectomy, laparoscopic fundoplication with or without gastro-
plasty, and laparoscopic Roux-en Y. Dysphagia decreased (0.42 
versus 1.82), and refl ux was better controlled after 2 years93 
(B). However, because the oesophageal problems might ex-
hibit late relapse in patients with SSc, surgery is not usually 
performed in individuals with scleroderma. 
Recommendation 10
PPIs improve refl ux oesophagitis, the symptoms of GER, and 
the local or respiratory complications. Surgery might be ben-
efi cial in the cases that are non-responsive to clinical treat-
ment.
11. What treatments are benefi cial for 
malabsorption syndrome in systemic sclerosis?
Oesophageal dysmotility and disorders of the intestinal func-
tion are remarkable manifestations of SSc and might exert 
signifi cant effects on the nutrient absorption and nutritional 
state of patients. With regard to the nutrient intake, anthro-
pometric measurements and biochemical nutritional state, 
individuals with SSc and gastrointestinal symptoms exhibit 
similar nutrient and energy intake but less consumption of 
fi bre, vegetables, and fruits compared to healthy patients. The 
risk of malnutrition was found to increase by 50% in individu-
als with SSc94 (B). Using the Malnutrition Universal Screening Tool 
(MUST), 18% of the individuals with SSc exhibited a high risk 
of malnutrition, which is associated with loss of appetite and 
abdominal distension95 (B).
Open-label studies elaborated on the benefi cial changes 
in antibiotic therapy, which no longer induced malabsorption 
symptoms, as shown by the normal results in the D-Xylose 
absorption test and the vitamin B12 absorption in patients 
with SSc after antibiotic treatment. The patients exhibited 
increased appetite and weight gain, anaemia was corrected, 
and pain and abdominal distension decreased96,97 (C).
In a study on a small number of patients with SSc and 
symptoms compatible with intestinal malabsorption non-
responsive to prokinetic agents, the use of octreotide 0.1 mg 
per subcutaneous (SC) route twice per day or octreotide 20 
mg/month per intramuscular (IM) route was shown to induce 
a signifi cant reduction of the severity of symptoms after 6 
months of treatment (0.7 ± 0.5, P = 0.003)86 (C).
Parenteral nutrition might be benefi cial in patients who 
exhibit signs of intestinal failure, bacterial overgrowth, mal-
absorption, and absence of response to antibiotics98 (B).
One study assessed the effect of rifamycin (400 mg three 
times per day) over 10 days in patients with SSc and signs of 
small-bowel intestinal overgrowth and noted eradication of 
the abnormal bacterial concentration in 73.3% of the patients 
and improved symptoms in 72.7%99 of the patients (B). Despite 
the lack of prospective randomised studies, antibiotic rota-
tion (metronidazole, tetracycline, amoxicillin, and ciprofl oxa-
cin, preferentially) is usually recommended in patients who 
suffer from chronic diarrhoea due to bacterial overgrowth and 
who have SSc and blind loop syndrome.
Recommendation 11
The use of prokinetic agents, such as octreotide, reduces the 
severity of the symptoms associated with intestinal dys-
motility. 
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Antibiotic rotation might eradicate the bacterial over-
growth. 
Nutritional support (parenteral nutrition) might be benefi -
cial in the most severe cases of malnutrition. 
12. What treatments are benefi cial for interstitial 
lung disease in systemic sclerosis?
Among other autoimmune diseases, the fast progressing ILD 
might be treated with cyclophosphamide (six to nine IV cy-
cles, 0.5 g/m2 body surface) combined with prednisolone 50 
mg followed by 5-7.5 mg/day as maintenance to improve the 
tolerance to exercise and lung function. The radiological fi nd-
ings at baseline remained stable after 10 months100 (C).
Patients with SSc, restrictive lung disease, dyspnoea, 
and evidence of infl ammatory ILD treated with cyclophos-
phamide PO (≤ 2 mg/kg/day) over 2 years exhibited 2.5% im-
provement of the forced vital capacity (FVC) that persisted 
24 months. The frequency of adverse events was higher in 
the patients treated with cyclophosphamide compared to 
the untreated patients, but there was no signifi cant differ-
ence in the frequency of severe adverse events between both 
groups38 (A). 
Patients with SSc for 14.2 ± 8.3 months and the presence of 
diffuse lung disease (ground-glass pattern) diagnosed using 
high-resolution computed tomography (CT) and deteriora-
tion of the FVC (forced vital capacity) and deterioration of the 
diffusion capacity of carbon monoxide (DLCO) can be treated 
with cyclophosphamide in monthly IV pulses (750-1,000 mg/
m2) combined with 1 g of methylprednisolone, and between 
treatment, steroids in daily oral doses (methylprednisolone, 6 
to 8 mg). After 6, 24, and 48 months of treatment, DLCO dete-
riorated in 23.1%, 33%, and 41.6% of the patients, improved in 
15.3%, 16.6%, and 33.3% of the patients, and remained stable 
in 61.5%, 50%, and 25% of the patients, respectively. After 6, 
12, 24, and 48 months of treatment, the FVC deteriorated in 
15.3%, 23.0%, 33.3%, and 33.3% of the patients, improved in 
7.6%, 15.3%, 16.6%, and 16.6%, and remained stable in 76.9%, 
61.5%, 50.5%, and 50.0%, respectively. The fi ndings on chest CT 
worsened in 38.4% of the patients and improved or remained 
stable in 61.5% of the patients. No complications occurred re-
lated to adverse events101 (C).
In patients with SSc and ILD, a combination of cyclophos-
phamide (1 g/m2/dose per month over 12 months) with pred-
nisone (60 mg/day over 1 month) did not produce any change 
in the FVC, forced expiratory volume (FEV), DLCO, or occur-
rence of infections after 3 years compared to cyclophospha-
mide alone102 (A).
The FVC and DLCO did not show any difference after treat-
ment of patients with SSc and diffuse ILD with cyclophospha-
mide PO (1-2.5 mg/kg/day) or IV (500-750 mg/m2) compared 
to untreated patients or patients treated with azathioprine 
over 12 months. However, the FVC and DLCO after 12 months 
exhibited signifi cant improvement when the data from ex-
perimental and observational studies were analysed together. 
Treatment with cyclophosphamide PO or IV did not exhibit a 
signifi cant difference103 (A).
All of the patients with ILD and SSc using cyclophospha-
mide, 0.4 g/m2/month, combined with prednisone, 0.8 mg/kg/
day, exhibited improvement after 12 months (as assessed by 
dyspnoea scores, CT, and FVC) but relapsed after 48 months. 
These fi ndings justify the use of maintenance therapy104 (B).
Corticosteroids in low doses (equivalent to predni-
sone 5-10 mg/day) are routinely used in Brazil as main-
tenance treatment for patients with ILD. In cases of dc-
SSc of < 5 years, special attention must be focused on 
the likelihood of triggering SRC (scleroderma  renal
crisis), which occurs in patients using prednisone ≥ 15 mg/
day. 
In a 4-week period, patients with SSc and progressive 
ILD (ground-glass or reticular changes at least to the venous 
confl uence) treated with bosentan (62.5 mg twice per day 
for 4 weeks, and subsequently 125 mg twice per day) over 
12 months did not exhibit improvement on the 6-min walk 
test, mortality rate, lung function test, or FVC compared to 
untreated patients105 (A).
A retrospective study that analysed 109 patients with dc-
SSc treated with mycophenolate mofetil noted a lower fre-
quency of clinically signifi cant lung fi brosis (P = 0.037) and 
better 5-year survival (P = 0.027) compared to 63 controls 
treated with other immunosuppressants106 (B). 
Clinical studies conducted with small numbers of patients 
showed that rituximab might be effi cient in the treatment 
of ILD in patients with SSc. One study assessed 15 patients 
treated with rituximab (two cycles with a dose of 375 mg/m2 
and 2-week interval) at baseline and after 24 weeks and dem-
onstrated a signifi cant improvement of the FVC (P = 0.0018) 
and DLCO (P = 0.017) associated with improvement of the skin 
score (P < 0.001) compared to six patients under conventional 
treatment41 (A). Improvement of FVC and DLCO persisted after 
2 years of treatment42 (A).
Recommendation 12
The ILD associated with SSc improves after treatment with 
cyclophosphamide. Mycophenolate mofetil and rituximab 
might represent alternative options for patients who are non-
responsive to cyclophosphamide. 
13. What treatments are benefi cial for pulmonary 
arterial hypertension in systemic sclerosis?
According to a recent meta-analysis, the prevalence of PAH is 
approximately 9% in patients with SSc107 (B). In that popula-
tion, PH might be pre-capillary (due to PAH or to ILD) or post-
capillary (secondary to left-heart disease). A precise diagnosis 
of the mechanisms involved is required for therapeutic deci-
sion-making. A recent study noted that a reduction of the vol-
ume of alveolar diffusion of carbon monoxide (< 70%) might 
be a risk factor for pre-capillary PH in SSc107 (B).
PH is a haemodynamic condition defi ned by average pul-
monary artery pressure of ≥ 25 mmHg in rest conditions, and 
pulmonary capillary pressure of ≤ 15 mmHg measured by 
right-heart catheterisation. 
Recommendations for the treatment of PAH were re-
cently published by the European Society of Cardiology and 
the European Respiratory Society108 (D). Treatment of PAH 
might be conventional or specifi c. Conventional treatment 
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includes general measures, such as oxygen therapy (in pa-
tients with oxygen saturation of < 90% in rest conditions or 
after exercise), diuretics (to correct fl uid overload in right-
heart failure), and digoxin (to treat right-heart failure com-
plicated by atrial arrhythmia), in addition to anticoagulation 
(indicated in “severe PAH”, which still lacks specifi c defi ni-
tion). Use of calcium-channel blockers, such as nifedipine, 
in high doses is restricted to the small group of patients (< 
2%) with positive vasoreactivity (reduction of mean pulmo-
nary artery pressure of ≥ 10 mmHg, thus reaching levels of ≤ 
40 mmHg, and improvement or normalisation of the cardiac 
index) to the acute vasodilator challenge in haemodynamic 
testing108 (D).
The specifi c treatment of PAH is based on the use of the 
groups of vasodilators that act on the three pathways in-
volved in its physiopathology: prostanoids (epoprostenol, ilo-
prost), ERAs (bosentan and ambrisentan), and phosphodies-
terase type-5 inhibitors (sildenafi l and tadalafi l)108 (D). 
Prostacyclin analogues
Epoprostenol per IV route was the fi rst specifi c agent ap-
proved for the treatment of PAH. A randomised clinical study 
compared patients exhibiting SSc spectrum disorders treated 
with IV epoprostenol (≤ 2 ng/kg of body weight per min) com-
bined with conventional treatment, and conventional treat-
ment alone, and reported the following results after 12 weeks: 
increase of 108 m in the distance walked in 6 min; reduction 
of 26 mmHg of the pulmonary artery pressure; reduction of 
25.5 mm/L/min of the vascular resistance; reduction of 50% 
of the functional class; and improvements in the dyspnoea 
and fatigue scores. The mortality rates did not exhibit a sig-
nifi cant difference. Adverse events included pain, nausea, an-
orexia, sepsis, cellulitis, haemorrhage, and pneumothorax109 
(A). However, in addition to its unavailability in Brazil, epo-
prostenol demands special care relative to the use of the con-
tinuous infusion pump.
Several prostacyclin analogues, such as (inhaled or IV) 
iloprost, treprostinil, and beraprost, also showed favourable 
results in patients with idiopathic PAH; however, few studies 
demonstrated their effi cacy in SSc108(D) 110(B).
Endothelin receptor antagonists
Bosentan was assessed in randomised clinical trials, where 
it promoted better results in the 6-min walk test associated 
with haemodynamic improvement in patients with PAH, in-
cluding PAH associated with SSc111,112 (A). In one clinical trial, 
patients with severe symptoms of primary PH or secondary 
to SSc (functional class III-IV), distance of the 150-500 m on 
the 6-min walk test, mean pulmonary pressure of ≥ 25 mmHg, 
pulmonary capillary pressure of < 15 mmHg, and pulmonary 
vascular resistance of > 240 dyn s cm−5 were randomly allo-
cated to treatment with bosentan 62.5 mg twice per day over 4 
weeks followed by 125 mg twice per day over 12 weeks, or pla-
cebo. The results of the treated group were as follows: greater 
distance on the 6-min walk test (difference of 76 m), improve-
ment of the cardiac index (increase of 1.0 L min–1m–2), reduc-
tion of the pulmonary vascular resistance (reduction of 415 
dyn s cm−5), and reduction in the dyspnoea index (Borg)111 (A).
Ambrisentan in doses of 5-10 mg/day showed favourable 
results in clinical studies on patients with idiopathic PAH, as 
well as in initial studies including patients with SSc113,114 (B).
Phosphodiesterase type-5 inhibitors
Sildenafi l was assessed in a randomised clinical trial conduct-
ed on 278 patients with idiopathic PH associated with connec-
tive tissue disorders (15% with SSc) or after surgical correc-
tion of pulmonary systemic shunt. The volunteers were given 
sildenafi l in doses of 20 mg, 40 mg, or 80 mg three times per 
day over 12 weeks, which were associated with increased dis-
tance in the 6-min walk test of 45 m (+13.0%), 46 m (+13.3%), 
and 50 m (+14.7%), respectively. Sildenafi l in all three doses 
induced improvement of the haemodynamic variables and 
the functional class. The most common adverse events were 
headache, face redness, hypotension, dyspepsia, and diar-
rhoea115 (A). A post hoc analysis of a subgroup of patients from 
that same study with SSc and other connective tissue disor-
ders showed increased distance on the 6-min walk test in the 
treated group. The functional class improved in 29% to 42% 
of the patients compared to 5% in the untreated group116 (B). 
Additionally, tadalafi l proved to be useful in the treatment 
of PAH. Tadalafi l was demonstrated to improve the exercise 
capacity, quality of life, and clinical state in a clinical study 
of 406 patients with PAH, of whom there were 95 volunteers 
with PAH that was associated with connective tissue disor-
ders117 (A).
Combined therapy
Combined therapy is also a target of several studies and might 
provide an alternative option for patients who do not respond 
well to monotherapy108 (D). 
Recommendation 13
The treatment of PAH in SSc includes conventional therapy 
and the following three classes of specifi c agents: prostacy-
clin analogues (epoprostenol, iloprost), endothelin receptor 
analogues (bosentan), and phosphodiesterase type-5 inhibi-
tors (sildenafi l, tadalafi l). 
14. What treatments are benefi cial for 
scleroderma renal crisis?
Approximately 13% of a cohort of individuals with SSc who 
were followed up for 4 years exhibited SRC. Approximately 
56% of the participants who eventually developed SRC were 
taking prednisone at study entry, compared with only 26% in 
the non-SRC patients (30%). In 90% of the patients, the dose 
of prednisone was ≤ 10 mg/day until the appearance of renal 
crisis118 (B). The 5-year mortality rate of patients with SSc was 
15%, and no difference was observed regarding the incidence 
of SRC or the mortality rate between patients using high (750-
1,000 mg/day) or low (125 mg on alternate days) doses of D-
penicillamine33 (A).
The incidence of SRC in patients with SSc might be 2.8%. 
Several drug-related factors might favour the occurrence of 
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SRC in patients with SSc, such as the use of non-steroidal 
anti-infl ammatory drugs (NSAIDs), steroids in high doses (> 
20 mg/day), cyclosporine, penicillamine, and surgical proce-
dures. The appearance of SRC was accompanied in the major-
ity of the patients by severe hypertension (94%), heart failure 
(56%), and microangiopathic haemolytic anaemia (MAHA) 
(81%), with a quick progression toward kidney failure with 
haematuria and proteinuria. The clinical progression of SRC is 
severe despite aggressive antihypertensive treatment (angio-
tensin-converting enzyme [ACE] inhibitors, vasodilators, and 
beta-blockers). The mortality is high over the fi rst days and 
weeks, and several patients might develop permanent kidney 
damage, thus requiring dialysis and kidney transplant. Treat-
ment with ACE inhibitors over 12 months was associated with 
satisfactory clinical progression in 50-61% of the cases118 (B).
SRC is characterised by the acute occurrence of arterial hy-
pertension and reduced kidney function (30% reduction of the 
glomerular fi ltration) and one of the following items: MAHA, 
hypertensive retinopathy, pulmonary oedema, oliguria or an-
uria, or kidney biopsy excluding other causes. Patients with 
dcSSc (78% of the cases) exhibited 10% increased risk of SRC 
compared to lcSSc. Approximately 36% of the patients did not 
require dialysis; 23% were subjected to dialysis and the kid-
ney function recovered (good prognosis); 41% were subjected 
to dialysis, but the kidney function did not recover (high mor-
tality); and 33% of the survivors required dialysis over 5 years. 
The survival rates were 82% at 1 year, 74% at 2 years, 71% at 3 
years, 59% at 5 years, and 47% at 10 years119 (B).
Acute and progressive oliguria due to kidney failure and 
acute and progressive hypertension in patients with SSc point 
to the occurrence of SRC, which affects 14% of the patients 4 
years after the onset of the fi rst non-Raynaud’s disease symp-
tom. As a rule, by the time SRC sets in, 20% of the patients are 
already using ACE inhibitors and 60% of the patients are using 
corticosteroids. After a 4-year follow-up, 56% of the patients 
required transient or long-term dialysis, none had a kidney 
transplantation, and the mortality of the patients who re-
ceived permanent dialysis (40%) was 90%. All of the patients 
were treated with ACE inhibitors, whose doses were increased 
after SRC set in. Several patients may require a combination 
with calcium-channel blockers, beta-blockers, and alpha- and 
beta-blockers. Survival at 1 year was 78%, whereas survival at 
5 years was 69%, and 50% and 41%, respectively, when chronic 
dialysis was required. The prognostic factors of mortality and 
chronic dialysis in SRC were as follows: age > 53 years old, 
normal arterial pressure, and need of dialysis at the onset of 
SRC120 (B).
The diagnostic criteria of hypertensive renal crisis in pa-
tients with SSc are as follows: systolic arterial pressure of > 
140 mmHg; diastolic arterial pressure of > 90 mmHg; increas-
es of the systolic pressure > 30 mmHg or of the diastolic pres-
sure > 20 mmHg associated with one of the following items: 
increase of the serum creatinine levels of > 50% compared to 
baseline or serum creatinine levels of > 120% of the normal 
value; proteinuria > two-fold; haematuria > two-fold; throm-
bocytopenia with < 100,000 platelets/mm3; haemolysis; and 
hypertensive encephalopathy. The diagnostic criteria of nor-
motensive renal crisis in patients with SSc are as follows: se-
rum creatinine of > 50% compared to baseline or > 120% of 
the normal value associated with one of the following items: 
proteinuria > two-fold; haematuria > two-fold; thrombocyto-
penia with < 100,000 platelets/mm3; haemolysis; and hyper-
tensive encephalopathy.
The distribution, clinical progression, and prognosis of the 
infected patients were assessed based on the following diag-
nostic criteria of hypertensive and normotensive SRC: 87% 
had hypertensive SRC, 22% were using ACE inhibitors or 5% 
renin-angiotensin blockers or 50% corticosteroids, before SRC 
set in. After 1 year, 50% of the patients received dialysis or had 
died121 (B).
With an overall incidence of 12% of SRC in patients with 
SSc, 20% of the patients developed SRC more than 6 months 
before the diagnosis of SSc, 70% developed SRC between 6 
months before and after the diagnosis of SSc, and 10% devel-
oped SRC 6 months after the diagnosis of SSc. Approximately 
20% of the patients exhibited satisfactory clinical progression 
and did not require dialysis. Of the 80% who required dialysis, 
only 20% could discontinue dialysis after 1 and 2 years. Kid-
ney transplantation was indicated in 30%; all of the patients 
used mycophenolate mofetil, azathioprine, cyclosporine, or 
tacrolimus; none exhibited transplant rejection; and the kid-
ney function recovered. The survival rate of the patients with 
SRC was 58% at 5 years and 40% at 10 years, and the survival 
rate of the patients without SRC was 90% at 5 years and 76% 
at 10 years122 (B).
Recommendation 14
Patients with SSc and renal crisis should be treated with ACE 
inhibitors in high doses. Dialysis and kidney transplantation 
are restricted to the patients in whom the kidney function 
does not recover quickly.  
15. What treatments are benefi cial for heart 
infection in systemic sclerosis? 
Approximately 10-35% of the patients with SSc might exhibit 
heart symptoms or arrhythmias. Cardiopulmonary infection 
contributes to 70% of the mortality, and heart involvement 
contributes to 11.4-36% of the deaths123-126 (C). Approximately 
52-55% of the patients without clinical evidence of heart dis-
ease have alterations in the coronary fl ow127,128 (C). A portion of 
the perfusion defects is fi xed, and reduced heart perfusion is 
found in 82% of the patients129,130 (C). The prevalence of coro-
nary disease was 22% in patients with SSc, and the distribu-
tion compared to the reference population (estimated events) 
was 47% with typical angina, 50% with atypical angina, and 
93% in patients with non-angina pain or with ventilatory re-
striction131 (C).
Published reports have indicated the benefi cial effects of 
vasodilators nifedipine, nicardipine, and captopril on the myo-
cardial perfusion after treatment with dipyridamole adminis-
tered intravenously132-135 (C). The benefi ts associated with the 
use of nifedipine (20 mg three times per day over 1 or 2 weeks) 
relative to the myocardial perfusion were demonstrated using 
positron emission tomography and magnetic resonance imag-
ing, which showed 38% increase of the global perfusion index 
and 39% reduction of the number of patients with more than 
one segment with perfusion defects129,136,137 (C). 
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Patients with SSc exhibited reductions of the left ven-
tricular ejection fraction (< 55%), right ventricular systolic 
depressed function, left ventricular diastolic depressed func-
tion, and 29% of the patients exhibited hypokinesis138-141(C). 
The benefi cial action of vasodilators in myocardial dysfunc-
tion was also exemplifi ed by the use of nicardipine (40 mg), 
which improved the left and right ventricular ejection frac-
tion129,138,142 (C). 
The following cardiac conduction defects were found in 
the electrocardiographic results of patients with SSc and 
ventricular arrhythmias concomitantly treated with anti-
arrhythmic agents (amiodarone, carvedilol, and calcium-
channel blockers), cyclophosphamide, and the following 
vasodilators: fi rst-degree atrioventricular block, left anterior 
fascicular block, and right bundle branch block, with cases 
> 1,000-5,000 premature ventricular contractions, nonsus-
tained ventricular tachycardia, ventricular and supraven-
tricular arrhythmias143(C). After 36 months of follow-up, 70% 
of the patients with implantable cardioverter-defi brillators 
exhibited normal heart rhythm and absence of shocks. The 
patients with ventricular tachycardia were reverted using 
the device144 (C).
Recommendation 15
The frequency of heart involvement (myocardial, coronary, 
and arrhythmic disorders) tends to be high in patients with 
SSc, and specifi c treatment is indicated, including calcium-
channel blockers (nifedipine, nicardipine), angiotensin-con-
verting enzyme inhibitors (captopril), amiodarone, carvedilol, 
and myocardial revascularisation. 
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Appendix
Search strategies per clinical question and 
number of located and selected articles
Question 1
What are the classifi cation criteria for systemic sclerosis?
(((Scleroderma, Systemic OR Systemic Sclerosis) AND 
specifi city[Title/Abstract]) OR ((Scleroderma, Systemic OR 
Systemic Sclerosis) AND (classifi cation OR criteria) AND 
(sensitiv*[Title/Abstract] OR sensitivity and specifi city[MeSH 
Terms] OR diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] 
OR diagnostic * [MeSH:noexp] OR diagnosis,differential[MeS
H:noexp] OR diagnosis[Subheading:noexp])))
Question 2
What is the role of nailfold capillaroscopy in the early diag-
nosis and follow-up of systemic sclerosis? 
((Scleroderma, Systemic OR Systemic Sclerosis) AND 
specifi city[Title/Abstract]) OR ((Scleroderma, Systemic OR 
Systemic Sclerosis) AND (classifi cation OR criteria) AND 
(sensitiv*[Title/Abstract] OR sensitivity and specifi city[MeSH 
Terms] OR diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] 
OR diagnostic * [MeSH:noexp] OR diagnosis,differential[MeS
H:noexp] OR diagnosis[Subheading:noexp])))
Located: 1,138
Selected: 12
Question 3
What is the role of the autoantibodies in the early diagnosis 
and follow-up of patients with systemic sclerosis?
(((Scleroderma, Systemic OR Systemic Sclero-
sis) AND specifi city[Title/Abstract]) OR ((Scleroder-
ma, Systemic OR Systemic Sclerosis) AND (classifi -
cation OR criteria) AND (sensitiv*[Title/Abstract] OR 
sensitivity and specifi city[MeSH Terms] OR diagnos*[Title/
Abstract] OR diagnosis[MeSH:noexp] OR diagnostic * 
[MeSH:noexp] OR diagnosis,differential[MeSH:noexp] OR 
diagnosis[Subheading:noexp])))
Located: 1,138
Selected: 28
Question 4
What treatments are benefi cial for skin thickening in sys-
temic sclerosis?
(Scleroderma, Systemic OR Systemic Sclerosis) AND 
(cutaneous OR skin OR thick* OR tissue) AND (randomised 
controlled trial[Publication Type] OR (randomised[Title/Ab-
stract] AND controlled[Title/Abstract] AND trial[Title/Ab-
stract]))
Located: 137
Selected: 21
Question 5
What treatments are benefi cial for subcutaneous calcinosis 
in systemic sclerosis?
Scleroderma, Systemic OR Systemic Sclerosis) AND (cal-
cinosis OR calcium OR subcutaneous)
Located: 1,374
Selected: 28
Question 6
What treatments are benefi cial for Raynaud’s phenomenon 
in systemic sclerosis?
(Scleroderma, Systemic OR Systemic Sclerosis) AND 
Raynaud AND (randomised controlled trial[Publication 
Type] OR (randomised[Title/Abstract] AND controlled[Title/
Abstract] AND trial[Title/Abstract]))
Located: 56
Selected: 20
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Question 7
What treatments are benefi cial for ischaemic ulcers in sys-
temic sclerosis?
(Scleroderma, Systemic OR Systemic Sclerosis) AND (ulcer 
OR ulcers OR ulceration OR ulcerative)
Located: 766
Selected: 8
Question 8
What are the maintenance treatments to prevent the recur-
rence of ischaemic ulcers in systemic sclerosis?
(Scleroderma, Systemic OR Systemic Sclerosis) AND (ulcer 
OR ulcers OR ulceration OR ulcerative) AND (recurrence OR 
relapse OR refractory OR follow-up OR cohort OR time factors 
OR response OR recrudescence OR prognosis)
Located: 270
Selected: 21
Question 9
What treatments are benefi cial for oesophageal and intesti-
nal hypomotility in systemic sclerosis?
(scleroderma, systemic OR systemic sclerosis) AND (esoph-
ageal diseases OR esophagus OR intestinal diseases OR intes-
tin* OR motility OR bloating OR distention) AND (scleroderma, 
systemic OR systemic sclerosis) AND (esophageal diseases OR 
esophagus OR intestinal diseases OR intestin* OR motility OR 
dismotility OR bloating OR distention)
Located: 397
Selected: 31
Question 10
What treatments are benefi cial for gastroesophageal refl ux 
and its complications in systemic sclerosis?
(scleroderma, systemic OR systemic sclerosis) AND (Gas-
troesophageal Refl ux OR Gastric Acid Refl ux OR GERD OR 
Esophageal Refl ux)
Located: 233
Selected: 12
Question 11
What treatments are benefi cial for malabsorption syndrome 
in systemic sclerosis?
(scleroderma, systemic OR systemic sclerosis) AND (Mal-
absorption Syndromes OR absorption OR malnutrition OR nu-
tritional status OR Intestine, Small OR Parenteral Nutrition OR 
Protein-Losing Enteropathies OR Exudative Enteropath*)
Located: 508
Selected: 19
Question 12
What treatments are benefi cial for interstitial lung disease in 
systemic sclerosis?
(scleroderma, systemic OR systemic sclerosis) AND 
(Lung Diseases, Interstitial OR Interstitial Pneumonia OR In-
terstitial Pneumonitis) AND ((clinical[Title/Abstract] AND 
trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical 
trial[Publication Type] OR random*[Title/Abstract] OR random 
allocation[MeSH Terms] OR therapeutic use[MeSH Subhead-
ing])
Located: 258
Selected: 26
Question 13
What treatments are benefi cial for pulmonary hypertension 
in systemic sclerosis?
(scleroderma, systemic OR systemic sclerosis) AND Hy-
pertension, Pulmonary AND ((clinical[Title/Abstract] AND 
trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical 
trial[Publication Type] OR random*[Title/Abstract] OR random 
allocation[MeSH Terms] OR therapeutic use[MeSH Subhead-
ing])
Located: 353
Selected: 7
Question 14
What treatments are benefi cial for scleroderma renal crisis?
(scleroderma, systemic OR systemic sclerosis) AND (Kid-
ney Diseases OR Acute Kidney Injury OR Renal crisis OR Hy-
pertension, Renal OR Renal Dialysis)
Located: 1495
Selected: 7
Question 15
What treatments are benefi cial for heart infection in systemic 
sclerosis?
(scleroderma, systemic OR systemic sclerosis) AND (car-
diac diseases OR heart diseases) AND ((clinical[Title/Abstract] 
AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR 
clinical trial[Publication Type] OR random*[Title/Abstract] OR 
random allocation[MeSH Terms] OR therapeutic use[MeSH 
Subheading])
Located: 267
Selected: 10
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